Monopar Therapeutics Inc. (MNPR) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Monopar Therapeutics Inc. (NASDAQ: MNPR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $70.32 (-2.21% 1D, market cap $482.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MNPR ranks #925 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MNPR carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -17.4%. By comparison, BLSM (BlossomHill Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC —, cap $483.4M) and FTH (Faeth Therapeutics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $484.5M). Among the 5-stock peer group, MNPR leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).
Per MNPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001645469), Monopar Therapeutics Inc. generated $0 in revenue, -$13.7M in net income, and -$12.2M in free cash flow against $140.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
FRED Regime × Technicals: 27% of 52W Range • RSI-14 at 37.5 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While MNPR currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($90.36) and Max Pain ($73.84) forces dealer call-delta covering toward $131.06.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Monopar Therapeutics Inc. (MNPR) dropped -2.21% to $70.32, trading at 27% of its 52-week range ($50.07 – $124.82). Stretched risk/reward at current multiples (-17% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Monopar Therapeutics Inc. (MNPR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Monopar Therapeutics Inc. (MNPR) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Monopar Therapeutics Inc. (MNPR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Monopar Therapeutics Inc. (MNPR) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Monopar Therapeutics Inc. (MNPR) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Monopar Therapeutics Inc. (MNPR) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Monopar Therapeutics Inc. (MNPR) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Monopar Therapeutics Inc. (MNPR) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MNPR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MNPR. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Monopar Therapeutics Inc. (MNPR) ranks #925 by composite RQD confidence (27/100, grade E) and #460 by equity capitalization ($482.7M). Within this direct 5-issuer industry benchmark cohort, MNPR leads on earnings valuation at N/A trailing P/E, while MNPR leads on capital efficiency and profitability with -17.4% ROIC and — gross margin. BLSM currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with MNPR at 27/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MNPR
ACTIVE
Monopar Therapeutics Inc. | E | 27/100 | — | — | -17.4% | -2.21% | $482.7M | Benchmark Subject |
| BLSM BlossomHill Therapeutics Inc. | D- | 42/100 | — | — | — | -9.60% | $483.4M | /blsm-vs-mnpr → |
| FTH Faeth Therapeutics Inc. | E | 29/100 | — | — | -35.0% | -0.32% | $484.5M | /fth-vs-mnpr → |
| EOLS Evolus Inc. | E | 27/100 | — | 66.3% | -35.0% | -2.26% | $496.7M | /eols-vs-mnpr → |
| CTMX CytomX Therapeutics Inc. | E | 14/100 | — | — | -20.5% | +2.18% | $499.0M | /ctmx-vs-mnpr → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Monopar Therapeutics Inc. (MNPR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$13.7M, operating cash flow of -$12.2M, and free cash flow of -$12.2M (-90.5% YoY). On the balance sheet, MNPR closed FY2025 with $140.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$13.7M | -$12.2M | -$12.2M | $140.7M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$15.6M | -$6.4M | -$6.4M | $60.3M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$8.4M | -$7.9M | -$7.9M | — | — |
As of 2026-11-02, Monopar Therapeutics Inc. (NASDAQ: MNPR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $70.32 (-2.21% 1D, market cap $482.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MNPR ranks #925 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MNPR carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -17.4%. By comparison, BLSM (BlossomHill Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC —, cap $483.4M) and FTH (Faeth Therapeutics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $484.5M). Among the 5-stock peer group, MNPR leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).
Per MNPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001645469), Monopar Therapeutics Inc. generated $0 in revenue, -$13.7M in net income, and -$12.2M in free cash flow against $140.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
MNPR last traded at $70.32 (-2.21% on volume of 197,771 shares), positioning the stock -22.18% below its 50-day simple moving average ($90.36) and -8.97% below its 200-day simple moving average ($77.25). Across its 52-week range of $50.07 to $124.82, MNPR sits at the 27.1% percentile with a 14-day RSI of 37.5 (NEUTRAL RANGE) and an implied next-earnings move of ±11.1% ($62.51 to $78.13).
Why MNPR Stock dropped -2.21% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-17% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, MNPR scores 27 out of 100, a letter grade of E, with the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 4/20 (ROIC of -17.4% and FCF yield of -2.53%); Whale 13F Flow at 4/20 (institutional accumulation and options positioning); Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 6/20 (Beta of 1.0 and sector sensitivity); and Forensic Balance Sheet at 10/20 (Altman Z-Score of 2.5, Piotroski F-Score of 3/9, and Debt/Equity of 0.5).
Taken together, the pillar scores indicate that the weakest areas are the cash-generation engine, institutional flow, and insider conviction, each of which scores at or below 4 of 20. The balance sheet pillar is the highest-scoring component, but a Piotroski F-Score of 3 out of 9 and negative free cash flow yield signal that the company is consuming rather than generating cash. For a prospective investor, the implication is that the rating's upside drivers are limited to balance-sheet resilience and macro beta alignment, while valuation support from operating cash flow is absent in the source data. This is an analytical framing of the rating, not personalized financial advice.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-16.7M | $-13.7M | N/A | $-12.2M | $61.8M | N/A |
| FY 2024 | $0.0M | $-16.2M | $-15.6M | N/A | $-6.4M | $45.8M | N/A |
| FY 2023 | $0.0M | $-8.8M | $-8.4M | N/A | $-7.9M | N/A | N/A |
Per the SEC financials, operating losses widened from $-8.8M in FY 2023 to $-16.7M in FY 2025, and cash increased from $45.8M to $61.8M over FY 2024 to FY 2025. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -17.4%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Balance sheet posture is therefore described by these reported ratios rather than by a reported debt figure, which the source data does not provide.
Risk watch items: the reported insider reduction, zero revenue, and negative free cash flow. Proprietary signals: none available in the Butterfly graph.
Real-time company headlines, analyst actions, and sector developments for Monopar Therapeutics Inc. (MNPR) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Monopar Therapeutics Inc. (MNPR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Monopar Therapeutics Inc. (MNPR) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Monopar Therapeutics Inc. (MNPR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Monopar Therapeutics Inc. (MNPR) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Monopar Therapeutics Inc. (MNPR) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Monopar Therapeutics Inc. (MNPR) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Monopar Therapeutics Inc. (MNPR) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Monopar Therapeutics Inc. (MNPR) market action, institutional positioning, and fundamental catalysts.
Welcome to the MNPR (Monopar Therapeutics Inc.) Roar Pit. Current RQD Composite is 27/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on MNPR, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Monopar Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on MNPR, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $71.91 (52-wk range $50.07 - $124.82), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).